Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03604692 · ClinicalTrials.gov registry record · Phase 1
A Phase 1/2 Study to Evaluate Axatilimab in Participants With Active cGVHD
A Phase 1 study, sponsored by Syndax Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 41
- Enrollment target
NCT03604692 is a Phase 1 study that has completed, run by Syndax Pharmaceuticals. The registered enrollment target is 41 participants.
The verdict
NCT03604692, a Phase 1 study, has completed, sponsored by Syndax Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 41 participants
- Enrollment target
Study Summary
This is a Phase 1/2, Open-label, Dose Escalation study to investigate axatilimab in participants with active chronic graft versus host disease (cGVHD).
Interventions
- DRUG axatilimab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2018-11-01 |
| Est. Completion | 2024-10-18 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03604692
The ClinicalTrials.gov registry entry for NCT03604692 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 41 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Syndax Pharmaceuticals, which has 25 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which axatilimab is the first listed.
NCT03604692 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03604692 about?
NCT03604692 is a clinical study titled "A Phase 1/2 Study to Evaluate Axatilimab in Participants With Active cGVHD". This is a Phase 1/2, Open-label, Dose Escalation study to investigate axatilimab in participants with active chronic graft versus host disease (cGVHD).
What is the current status of trial NCT03604692?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 41 participants. The study started on 2018-11-01. Estimated completion is 2024-10-18.
What interventions are being tested in trial NCT03604692?
The interventions under investigation include: axatilimab (DRUG).
Who is sponsoring clinical trial NCT03604692?
This trial is sponsored by Syndax Pharmaceuticals, which has 25 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.